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introduction
In 1970, Ben Hesper and Paulien Hogeweg coined the term 
bioinformatics to refer to “the study of information processes 
in biotic systems”. In consequence, bioinformatics was placed 
as a field parallel to biochemistry and biophysics.1 Since then, 
the digital world expanded and the definition of bioinformatics 
took on a whole new meaning. It now combines the fields of 
biology, computer science, engineering, mathematics, and 
statistics to decipher biological data and make sense of it in 
translational research.
Over the past decade, the advent of high throughput or 
next generation sequencing (NGS) has accelerated the rate at 
which genes and co-regulated gene networks are discovered. 
Indeed, a vast amount of data is now available, in particular 
from the completion of the human genome project in 2003. 
Together, this data is being used to modulate disease outcome, 
predisposition, and progression.2 For this reason, the science of 
clinical bioinformatics has become one of the fastest growing 
areas of development within the healthcare environment. It is an 
important component in laboratories that generate and interpret 
data from molecular genetics testing. Overall, the aim of clinical 
bioinformatics is to address the challenges in initial diagnosis, 
prognosis, and therapies of patients3 with diseases such as cancer, 
neurodegenerative and psychiatric disorders, amongst others.
cancer
In clinical medicine, it has become apparent that there is a need 
to develop and introduce advanced and new bioinformatics 
methodologies to answer the specific question of cancer.4 
In order for cancer bioinformatics to be effective, the tools 
must thus concentrate on the communication, metabolism, 
proliferation, and signalling of the disease. In particular, 
cancer bioinformatics is expected to have a significant role in 
the identification and validation of biomarkers. For example, 
one of the strategies is to evaluate and monitor biomarkers at 
different stages and time points during cancer development. 
Identified as dynamic network biomarkers, these markers should 
compare with clinical informatics, such as patient complaints, 
history, symptoms, and therapies. In addition, these biomarkers 
should also correlate to biochemical analyses, imaging profiles, 
pathologies, physician’s examinations, and other measurements.5
For instance, through a genetic screen of hepatic cellular 
carcinoma, Sawey et al.6 discovered that a common alteration in 
liver cancer (11q13.3 amplification) causes the activation of the 
fibroblast growth factor 19 (FGF19), a hormone that regulates 
bile production with effects on glucose and lipid metabolism. In 
turn, through subsequent bioinformatics analysis with mouse 
models and RNAi, it was found that activation of FGF19 results 
in selective responsiveness to FGF19 inhibition. Therefore, 
Sawey et al. propose for the 11q13.3 amplification to be used 
as a biomarker for patients who, in all likelihood, will respond 
to anti-FGF19 therapies. In a somewhat similar approach, 
Baert-Desurmont et al.7 revealed that a combination of single 
nucleotide polymorphisms (8q23, 15q13 and 18q21 SNPs) could 
explain an increased risk for colorectal cancer.
Using genome-wide screening methods, aberrant expression 
profiles of microRNAs (miRNAs) have also been identified in 
human cancers, thus revealing their potential as diagnostic and 
prognostic biomarkers of cancer.8 Now, in order to infer the 
regulatory processes of miRNAs, bioinformatics approaches 
are fundamental. For example, Laczny et al.9 developed a 
comprehensive and integrative tool, called miRTrail, to generate 
reliable and robust data on deregulated pathogenic processes 
which could offer insights into the interactions between genes 
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and miRNAs. In fact, the use of miRTrail on melanoma samples 
demonstrated how this platform opened new avenues for 
investigating a wide range of diseases, including cancer.
In clinical practice and medical research, medical image 
processing facilitates the accurate, initial detection and diagnosis 
of cancer. Indeed, medical imaging - imaging in clinical pathology, 
nuclear magnetic resonance imaging, positron emission 
tomography, and ultrasonic computed tomography - is one of the 
most important factors in the application of cancer bioinformatics. 
Kimori et al.10 for instance, used a mathematical morphology-based 
approach to enhance fine features of a lesion with high suppression 
of surrounding tissues. Here, the effectiveness of the method was 
evaluated in terms of the contrast improvement ratio as applied 
to three kinds of medical images: a chest radiographic image, a 
mammographic image, and a retinal image.
Overall, the aim of cancer bioinformatics is to continue 
developing tools so that the right treatment is provided to the 
right patient at the right time, based on the characteristics of 
each patient’s tumour; in other words, tailored bioinformatics.
neurodegenerative diseases
It is known that the economical and societal costs of 
neurodegenerative diseases are accelerating. Therefore, there 
is a demand to find new solutions to resolve the situation.11 
However, having said that, progress in this area has proved to be 
challenging. In part, this is because the cause of diseases such 
as Alzheimer’s (AD) or Parkinson’s disease (PD) is not known, 
making them difficult to understand.12 In addition, while 
understanding these diseases on a molecular level could lead 
to the development of better biomarkers and treatments, the 
enormous amount of data involved renders it an arduous task. 
For this reason, bioinformatics approaches are used to manage 
data from high-throughput technologies, pushing forward the 
frontiers of this field.
In regard to late onset AD and PD, both have an obvious 
genetic component, however, their genetic architecture is 
complex, with just a few, constant, associated risk factors. It 
is therefore possible that undiscovered AD and PD-related 
genes exist. Kim et al.13 using biomedical text mining, were 
able to pinpoint genes that have a direct relationship with both 
neurodegenerative diseases. In another approach, Hofmann-
Apitius et al.12 developed a bioinformatics and modelling 
method based on patient data available to the public. Here, the 
work presented was driven through AETIONOMY, a public- 
private partnership between the European Union and the 
pharmaceutical industry association EFPIA.
ALS, short for amyotrophic lateral sclerosis, is another 
neurodegenerative disease, but one that affects nerve cells in 
the brain and the spinal cord. To date, there is a vast volume 
of data capturing this motor neurone disease. In consequence, 
there is a corresponding need for storage and interpretation. 
In keeping with this, Abel et al.14 presented an ALS online 
bioinformatics database (ALSoD) combining genotype, 
phenotype, and geographical information with associated 
analysis tools. Likewise, PRO-MINE (PROtein Mutations 
In NEurodegeneration)15 is a database describing all TDP-
43 disease mutations identified up to now; TDP-43 is a 
multifunctional RNA-binding protein found in AD, ALS, and 
also frontotemporal lobar degeneration. 
allergic and psychiatric disorders
In 2008, TIME magazine named 23andMe the invention of 
the year. 23andMe provides a home-based saliva collection kit 
that decodes the genomic DNA of adults and interprets their 
genetic health risks, with results accessible online. In particular, 
it tests for ten diseases, including AD, PD, and some rare blood 
diseases. It is important to note that the 23andMe kit describes 
if an individual has a higher risk of developing a disease but 
it is not intended to diagnose disease. It is meant to provide 
information that can be used to inform life decisions.
Using the 23andMe gene pool, Hyde et al. 16 discovered 15 
genetic loci associated with a risk of major depression in people 
of European descent. In a similar approach, genome-wide 
analyses for personality traits identified 6 loci with correlations 
to psychiatric disorders.17 In addition, through a multi-trait 
analysis of a genome-wide association study, Turley et al.18 
identified loci for depressive symptoms, neuroticism, and 
subjective well-being. Using this 23andMe gene pool, scientists 
have also discovered that asthma, eczema and hay fever share 
a genetic origin, in part due to shared genetic risk variants that 
dysregulate the expression of immune-related genes.19 
conclusion
Overall, clinical bioinformatics is the critical step to discovering 
and developing new diagnostics and therapies for diseases. Here, 
we described cancer, neurodegenerative and psychiatric disorders, 
however, bioinformatics has been used in other disorders as well, 
such as acute rejection after renal transplantation20 and lung 
diseases.21 In addition, bioinformatics has been used in studies 
of model organisms such as Saccharomyces cerevisiae (yeast), 
Drosophila melanogaster (flies), and Mus musculus (mice), which 
in turn shed light onto non-model organisms such as humans.
It is evident that bioinformatics will continue to push the 
boundaries of medicine and shape clinical testing for the future. 
Just like microscopes, computers have become a requirement, 
and the job of a bioinformatician is now an integral part of 
research laboratories and also in the clinical setting. In the 
future, success will depend on improved analytics, annotations, 
software to deliver this information, and systems to capture the 
realised knowledge.22 
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blurb
The journey in Embryoland is truly an amazing odyssey. And, this beautifully illustrated 
narrative offers readers, young or old, an incredibly imaginative journey to their own 
beginnings. Biology informs us about the researched scientific system of facts as to what 
happens for a new little body coming to life. The authors and the artist have managed to create a vibrant living vision of every 
human being conceived, grown, developed and matured over the nine months before being born. The intricate fascinating 
science of embryology is explained through this story recounted by the child herself as she is musing and dreaming about 
her own beginnings. This book has been written for any child, parent, educator or healthcare professional, who wishes 
to understand the journey from conception to birth. While adhering to accurate scientific facts based upon the advice of 
Prof. Jean Calleja Agius from the Department of Anatomy, Faculty of Medicine and Surgery at the University of Malta, 
the story itself has been written by the prenatal psychologist Olga Gouni from Cosmoanelixis Academy in Athens, Greece, 
and embellished by numerous illustrations by a child, Amelie, based on her understanding of the concepts of embryology. 
There is also a section at the end for activities and games related to embryology. This book has been ‘conceived’ as part of 
the COST Action ISI405: Building Intrapartum Research Through Health - an interdisciplinary whole system approach 
to understanding and contextualising physiological labour and birth (BIRTH) , and is intended to disseminate knowledge 
related to human conception, embryo development and birth to the general public, including children! 
once upon a time in emBryoland
Olga Gouni (Author, Editor)   |   Jean Calleja Agius (Author)   |   Amelie Calleja (Illustrations)
Price: €22   |   Published: On Amazon’s CreateSpace Independent Publishing Platform in 2018
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